Xencor, Inc. (NASDAQ:XNCR) Expected to Post Quarterly Sales of $8.15 Million
Analysts expect Xencor, Inc. (NASDAQ:XNCR) to post $8.15 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Xencor’s earnings. The highest sales estimate is $10.30 million and the lowest is $6.00 million. Xencor reported sales of $66.01 million in the same quarter last year, which would suggest a negative year over year growth rate of 87.7%. The company is expected to announce its next quarterly earnings results on Tuesday, August 1st.
According to Zacks, analysts expect that Xencor will report full-year sales of $8.15 million for the current year, with estimates ranging from $18.80 million to $35.10 million. For the next financial year, analysts anticipate that the business will post sales of $28.10 million per share, with estimates ranging from $20.00 million to $36.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Xencor.
Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.06. Xencor had a net margin of 18.19% and a return on equity of 5.98%. The firm had revenue of $4.34 million during the quarter, compared to analyst estimates of $8.15 million.
A number of analysts recently weighed in on XNCR shares. Zacks Investment Research downgraded Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Wedbush restated an “outperform” rating and issued a $29.00 target price on shares of Xencor in a research report on Wednesday, May 10th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $28.67.
In other news, insider Edgardo Baracchini, Jr. sold 10,568 shares of the business’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was sold at an average price of $26.01, for a total transaction of $274,873.68. Following the transaction, the insider now directly owns 9,818 shares of the company’s stock, valued at $255,366.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce L. A. Carter sold 12,400 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $22.19, for a total value of $275,156.00. Following the transaction, the director now directly owns 83,344 shares in the company, valued at $1,849,403.36. The disclosure for this sale can be found here. Insiders sold a total of 46,238 shares of company stock worth $1,037,822 over the last ninety days. Insiders own 4.14% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Norges Bank acquired a new position in Xencor during the fourth quarter valued at about $15,601,000. Metropolitan Life Insurance Co. NY boosted its position in Xencor by 5.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 24,914 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 1,227 shares during the period. Creative Planning boosted its position in Xencor by 2.7% in the first quarter. Creative Planning now owns 38,400 shares of the biopharmaceutical company’s stock valued at $919,000 after buying an additional 1,000 shares during the period. Marshall Wace North America L.P. acquired a new position in Xencor during the first quarter valued at about $1,652,000. Finally, Adams Diversified Equity Fund Inc. boosted its position in Xencor by 2.9% in the first quarter. Adams Diversified Equity Fund Inc. now owns 28,100 shares of the biopharmaceutical company’s stock valued at $672,000 after buying an additional 800 shares during the period. 75.00% of the stock is currently owned by hedge funds and other institutional investors.
Xencor (XNCR) traded down 0.352% on Friday, hitting $24.085. The stock had a trading volume of 58,719 shares. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of 68.229 and a beta of 2.13. Xencor has a 1-year low of $18.18 and a 1-year high of $29.38. The company has a 50-day moving average price of $21.92 and a 200-day moving average price of $23.19.
COPYRIGHT VIOLATION NOTICE: “Xencor, Inc. (NASDAQ:XNCR) Expected to Post Quarterly Sales of $8.15 Million” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/07/25/xencor-inc-nasdaqxncr-expected-to-post-quarterly-sales-of-8-15-million.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.